| Similar Articles |
|---|
 |
Fast Company
July 1, 2007 |
Going on the Gold Standard What it takes for your company to join the cancer fight.   |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
BusinessWeek
September 30, 2009
Arlene Weintraub |
J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D. |
Nurse Practitioner
December 2008
Darlene P. Peters |
Colon Cancer Screening: Recommendations and Barriers to Patient Participation Advanced practice nurses and nurse researchers can play a vital role in improving colon cancer screening among patients. |
Managed Care
March 2007
Lola Butcher |
Plans Put Greater Emphasis On Cancer Management Increasingly, health plans are rolling out services designed to help cancer patients and, before that, plan members at a high risk of cancer, to improve their health care and, in doing so, limit costs. |
Pharmaceutical Executive
June 1, 2013
Ben Comer |
From Locked Box to Data Sphere Project Data Sphere aims to liberate clinical trial data sets from industry and academic vaults, in an attempt to catalyze cancer research and discovery. |
Chemistry World
August 22, 2013
Phillip Broadwith |
J&J buys Aragon's prostate cancer arm Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. |
American Family Physician
February 1, 2001
Thomas J. Gates |
Screening for Cancer: Evaluating the Evidence This article reviews the kind of evidence required to justify screening tests for cancer, with the goal of guiding family physicians through current and future screening controversies... |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
| AskMen.com |
Good Health Care News New advice from the American Cancer Society puts a sharper focus on the risks of prostate cancer screening, emphasizing that annual testing can lead to unnecessary biopsies and treatments that do more harm than good. |
AskMen.com
Whitney F. Jones |
Colon Cancer And Polyps: What You Need To Know It would surprise many to learn that colon cancer is the third leading cause of death by cancer in American men. |
BusinessWeek
July 21, 2003
Gene G. Marcial |
A Rosier Millennium? Jump into Millennium Pharmaceuticals stock. That's the word from some Millennium trackers who think its recent fall -- from 17.20 in mid-June to 14 on July 1 -- was unwarranted. It is now at 15. |
The Motley Fool
January 24, 2006
Stephen D. Simpson |
Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did. |
BusinessWeek
June 18, 2007
Arlene Weintraub |
Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific. |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
BusinessWeek
February 16, 2004
Catherine Arnst |
Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs. |
BusinessWeek
July 17, 2006
Bruce Einhorn |
A Key New Ally In The Cancer War China and its Western trade partners are fighting together on at least one front: the war on cancer. |
The Motley Fool
May 28, 2009
Brian Orelli |
Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us. |
Managed Care
August 2007
Martin Sipkoff |
Soaring Price of Cancer Drugs Leads Plans To New Approaches Insurers are trying different methods, from pay for performance to promoting preventive care, to hold down cost of chemotherapy drugs. |
American Family Physician
March 15, 2001 |
Cancer Screening Guidelines Faced with the broad, and sometimes conflicting, range of recommendations for cancer screening, family physicians must determine the most reasonable and up-to-date method of screening... |
Pharmaceutical Executive
February 1, 2013
William Looney |
In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer. |
Health
October 10, 2008 |
Cervical Cancer FAQ Signs, symptoms, prevention, and treatments are some of the topics explained here. |
The Motley Fool
November 22, 2006
Brian Lawler |
Dueling Fools: Johnson & Johnson Bear J&J's dividend does provide investors with some degree of income, but a CD does, too -- without a health-care stock's risks. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
AskMen.com
Jacob Franek |
Prostate Cancer Symptoms, Screening & Diagnosis Despite the facts that prostate cancer is the No. 1 cancer occurring in men (aside from skin cancers) and the second leading cause of cancer death (behind lung cancer), many men are still unfamiliar with this highly treatable disease. |
The Motley Fool
October 26, 2010
Ralph Casale |
Where We Are in the War on Cancer A summary of the roundtable discussions at Xconomy's recent event, "Boston's War on Cancer." |
The Motley Fool
April 26, 2004
Alyce Lomax |
Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug. |
The Motley Fool
November 22, 2006
Steven Mallas |
Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock. |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
BusinessWeek
November 29, 2004
Kerry Capell |
"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
BusinessWeek
November 12, 2009
Catherine Arnst |
10 Ways to Cut Health-Care Costs Right Now Employers and hospitals don't have to wait for Congress to address inefficiencies and waste. |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
BusinessWeek
June 6, 2005
Catherine Arnst |
Better Odds Against Breast Cancer New treatments for breast cancer are more effective, and easier to live with |
BusinessWeek
April 23, 2007
Arlene Weintraub |
Under The Weather At J&J Johnson & Johnson's three big products have seen setbacks, with little in sight to replace them. |
CIO
May 29, 2014
Stephanie Overby |
CIOs Join Forces to Battle Cancer A coalition of healthcare IT chiefs are on a mission to put cancer out of business and share IT best practices, technology tips, and personal support. |
The Motley Fool
May 8, 2009
Brian Orelli |
Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector? |
BusinessWeek
December 20, 2004
Amy Barrett |
J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant. |
BusinessWeek
March 8, 2004
Arlene Weintraub |
And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why. |
Scientific American
January 2009
John Rennie |
A Molecular Checkup: The Nano Future of Medicine The Editor in Chief of Scientific American introduces the February 2009 issue |
The Motley Fool
October 27, 2006
Jack Uldrich |
Nanotech and the War on Cancer New imaging advances in nanotechnology will help speed cancers' end. What does it mean for investors? |
American Journal of Nursing
September 2009
Lockwood-Rayermann et al. |
Original Research: Women's Awareness of Ovarian Cancer Risks and Symptoms Objective: To assess how well informed women ages 40 and older are of ovarian cancer symptoms and risk factors. |
AskMen.com
Jacob Franek |
Men's Health Screening Guide Use this men's health screening schedule to stay in top health. |
Fast Company
David Lumb |
Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period. |
Science News
May 13, 2000 |
Cancer Net CancerNet is a huge compendium of information on cancer assembled by the National Cancer Institute.... |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
Wired
Thomas Goetz |
Why Early Detection Is the Best Way to Beat Cancer By getting regular blood tests, doctors may be able to diagnose cancer early, giving the patient a 90 percent chance of survival. |
The Motley Fool
September 17, 2010
James Early |
Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care. |
American Family Physician
March 15, 2007
Mark H. Ebell |
Point-of-Care Guides: Estimating 10-Year Mortality Risks Clinical Question: What is a patient's risk of dying from vascular disease, cancer, infection, an accident, or any cause within the next 10 years?... Evidence Summary... Applying the Evidence... etc. |
